Early detection of ovarian cancer is crucial, with a 5-year survival rate exceeding 90%. Once this early window has been missed, the 5-year survival rate precipitously drops below 50%.
Different drug delivery agents, including synthetic polymers, virus-based vectors, lipid-based vectors, and extracellular vesicles (EVs), have been explored previously.
Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.
Researchers in Prof. A.C. Matin's laboratory have developed a versatile exosome (extracellular vesicle, "EV") drug delivery platform that can selectively target therapeutic agents to tumors or other tissues that overexpress extracellular receptors.